Assessing the Performance of Deep Learning for Automated Gleason Grading in Prostate Cancer.


Journal

Studies in health technology and informatics
ISSN: 1879-8365
Titre abrégé: Stud Health Technol Inform
Pays: Netherlands
ID NLM: 9214582

Informations de publication

Date de publication:
22 Aug 2024
Historique:
medline: 23 8 2024
pubmed: 23 8 2024
entrez: 23 8 2024
Statut: ppublish

Résumé

Prostate cancer is a dominant health concern calling for advanced diagnostic tools. Utilizing digital pathology and artificial intelligence, this study explores the potential of 11 deep neural network architectures for automated Gleason grading in prostate carcinoma focusing on comparing traditional and recent architectures. A standardized image classification pipeline, based on the AUCMEDI framework, facilitated robust evaluation using an in-house dataset consisting of 34,264 annotated tissue tiles. The results indicated varying sensitivity across architectures, with ConvNeXt demonstrating the strongest performance. Notably, newer architectures achieved superior performance, even though with challenges in differentiating closely related Gleason grades. The ConvNeXt model was capable of learning a balance between complexity and generalizability. Overall, this study lays the groundwork for enhanced Gleason grading systems, potentially improving diagnostic efficiency for prostate cancer.

Identifiants

pubmed: 39176576
pii: SHTI240605
doi: 10.3233/SHTI240605
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1110-1114

Auteurs

Dominik Müller (D)

Faculty of Applied Computer Science, University of Augsburg, Germany.
Institute for Digital Medicine, University Hospital Augsburg, Germany.

Philip Meyer (P)

Institute for Digital Medicine, University Hospital Augsburg, Germany.

Lukas Rentschler (L)

Institute for Digital Medicine, University Hospital Augsburg, Germany.
Institute for Pathology, University Hospital Augsburg, Germany.

Robin Manz (R)

Institute for Digital Medicine, University Hospital Augsburg, Germany.

Daniel Hieber (D)

Institute for Pathology, University Hospital Augsburg, Germany.
Institute DigiHealth, Neu-Ulm University of Applied Sciences, Germany.
Bavarian Cancer Research Center (BZKF), Augsburg, Germany.

Jonas Bäcker (J)

Institute for Digital Medicine, University Hospital Augsburg, Germany.

Samantha Cramer (S)

Institute for Digital Medicine, University Hospital Augsburg, Germany.

Christoph Wengenmayr (C)

Institute for Digital Medicine, University Hospital Augsburg, Germany.

Bruno Märkl (B)

Institute for Pathology, University Hospital Augsburg, Germany.

Ralf Huss (R)

Institute for Pathology, University Hospital Augsburg, Germany.
BioM Biotech Cluster Development GmbH, Germany.

Frank Kramer (F)

Faculty of Applied Computer Science, University of Augsburg, Germany.

Iñaki Soto-Rey (I)

Institute for Digital Medicine, University Hospital Augsburg, Germany.

Johannes Raffler (J)

Institute for Digital Medicine, University Hospital Augsburg, Germany.
Bavarian Cancer Research Center (BZKF), Augsburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH